Remgro Ltd Ord (RMGOF) Q2 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

gentlemen, and welcome to the Remgrove Limited interim results presentation. All participants will be in listen-only mode. There will be an opportunity to ask questions later during the conference. If you should need assistance during the call, please signal an operator by pressing star, then zero. Please note that this call is being recorded. I would now like to turn the conference over to Yanni Duran. Please go ahead, sir. Good morning, everybody. Thank you for joining us this morning and welcome to our interim results presentation for the six months ended 31st of December 2024. Today's presentation will focus predominantly on reporting on our financial performance for the interim period. In addition, I will, as has become regular practice, touch on key strategic priorities. but not in a great amount of detail as we'll be hosting a capital markets day in a few weeks where we will unpack our strategic priorities in more detail. With that said, the outline of today's presentation will be as follows. Firstly, I will give an overview of the salient features of our results for the period under review. This will include providing you with a high-level recap of our key strategic priorities which remain consistent with those communicated at our previous results presentation and also a sense of our progress against delivery against these priorities. Secondly, our CFO Neville Williams will unpack in more detail our results for this period. Thirdly, We will then be giving an update on some of our key investments, namely Mediclinic, Heineken Beverages, CIVH, and RCL Foods. The CFO of Mediclinic, Jurgens Myberg, will speak to Mediclinic's results thereafter, and for the first time, the CFO of Heineken Beverages, Lucas Verweij, will do the same for Heineken Beverages. Then the C...